Key facts
- This page summarizes Alejandra Carvajal's Form 4 filing for Mersana Therapeutics, Inc. (MRSN).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Jan 2025, 19:18.
Alejandra Carvajal - 15 Jan 2025 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)
- Reporting relationship
- SVP, Chief Legal Officer
- Issuer ticker
- MRSN
- Reported as of
- 15 Jan 2025
- Net transaction value
- -$2,956
- SEC form
- 4
- Accepted by SEC
- 17 Jan 2025, 19:18:50 UTC
- Prior SEC filing
- 16 Jan 2025
- Next SEC filing
- 06 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alejandra Carvajal
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alejandra Carvajal filed Form 4 for Mersana Therapeutics, Inc. (MRSN) on 17 Jan 2025.
Change
- Previous filing in this sequence was filed on 16 Jan 2025.
- Current net transaction value: -$2,956.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRSN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +12,500
- Change %
- +18%
- Price
- $0.000000
- Shares after
- 83,392
- Date
- 15 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
MRSN
transaction
Common Stock
Sale
- Transaction value
- $2,956
- Shares
- -5,096
- Change %
- -6.1%
- Price
- $0.5800
- Shares after
- 78,296
- Date
- 16 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRSN
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -12,500
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 15 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- Footnotes
- F4, F5
MRSN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +243,750
- Change %
- Price
- $0.000000
- Shares after
- 243,750
- Date
- 15 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 243,750
- Exercise price
- $0.6400
- Footnotes
- F6
MRSN
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +54,167
- Change %
- Price
- $0.000000
- Shares after
- 54,167
- Date
- 15 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 54,167
- Exercise price
- Footnotes
- F4, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2024.
Footnote F2
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
Footnote F3
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F4
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
Footnote F5
25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.
Footnote F6
The option shall vest in equal quarterly installments over four years from the date of grant.
Footnote F7
The RSUs shall vest in equal annual installments over four years from the date of grant.